TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Update

TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 12,000 shares, a decrease of 43.7% from the December 31st total of 21,300 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 275,000 shares, the short-interest ratio is currently 0.0 days.

TherapeuticsMD Price Performance

NASDAQ TXMD remained flat at $1.08 during trading hours on Friday. 12,606 shares of the company were exchanged, compared to its average volume of 854,330. TherapeuticsMD has a one year low of $0.70 and a one year high of $2.75. The business’s 50-day simple moving average is $1.18 and its 200-day simple moving average is $1.49.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.05) EPS for the quarter. The firm had revenue of $0.55 million for the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative return on equity of 14.08%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on TherapeuticsMD in a report on Tuesday, January 14th. They set a “hold” rating for the company.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.